Journal
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
Volume 19, Issue 4, Pages 365-372Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ACI.0000000000000540
Keywords
biologics; biomarker; chronic rhinosinusitis; endotype; nasal polyp
Categories
Funding
- Beijing Advanced Innovation Center for Food Nutrition and Human Health (Beijing Technology and Business University (BTBU)) [20181045]
- Program for Changjiang Scholars and Innovative Research Team [IRT13082]
- National Key R&D Program of China [2016YFC20160905200, 2018YFC0116800]
- National Science and Technology Infrastructure Program of China during the 12th Five-Year Plan Period [2014BAI07B04]
- National Natural Science Foundation of China [81420108009, 81630023, 81570895, 81870698, 81470678]
- Research of Capital Health Security and Cultivation [Z18110700160000]
- Beijing Municipal Administration of Hospitals' Mission Plan [SML20150203]
- Capital Health Development Research Program [2016-1-2052]
- Beijing Municipal Administration of Hospitals' Innovation Program of Clinical Techniques [XMLX201816]
- Beijing Municipal Administration of Hospitals' Youth Programme [QML20150202]
- Beijing Hundred-Thousand-Ten Thousand Founding Program [2018A10]
Ask authors/readers for more resources
Purpose of review Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory condition with different endotypes between patients from eastern or western countries. Targeted biologics are currently used to treat CRSwNP, but the outcomes widely vary. This review focuses on the present use of biologics for treating CRSwNP. Recent findings Monoclonal biologics have been used as an innovative therapy for multiple allergic diseases and comorbid allergic conditions. Over the past several decades, numerous biomarkers have been investigated and were found to be closely correlated with CRSwNP, improving the understanding of inflammatory patterns and endotype classifications for CRSwNP and prompting discussion regarding the use of biologics in CRSwNP. Efficacies vary in reports of different research groups, but it has been found that patients with TH-2-driven inflammatory patterns respond better to the use of biologics than those with non-TH-2-driven CRSwNP. These findings suggest the importance and urgency of developing criteria for biologics in CRSwNP. Summary Precisely determining patient criteria, identifying treatment biomarkers based on endotyping for CRSwNP and determinations of contraindications for long-term utilization may be useful for optimizing treatment strategies and improving the therapeutic efficacy of biologics to achieve long-term control starting at early stages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available